Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Postmenopausal women with osteoporosis (Lumbar spine or femoral neck BMD or total hip T-score less than or equal to-2.5)~Exclusion Criteria:~1. Women with vertebral (L1-L4) abnormalities that preclude accurate measurement by DEXA.~2. Women on medications that are known to affect bone for more than 7 days in the past 6 months.~3. Currently taking systemic prednisone, inhaled steroids, anticoagulants, anticonvulsants.~4. History of rhPTH use or known hypersensitivity to study drug.~5. Vitamin D3 deficiency (Vitamin D3 \< 20 ng/ml).~6. Abnormal thyroid function.~7. History of kidney disease.~8. Any history of hypercalciuria, hypercalcemia or hyperparathyroidism.~9. History of active or treated tuberculosis or significant liver disease or gastrointestinal disease or cancer.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Drug Group (Type: EXPERIMENTAL): Osteoform
- Control group (Type: ACTIVE_COMPARATOR): SHELCAL

Based on this trial design, predict the completion outcome and termination type (if applicable).